Wide Ranks

ALXO

ALX Oncology Holdings Inc.

1.51

Top Statistics
Market Cap 79 M Forward PE -0.6622 Revenue Growth 0.00 %
Current Ratio 4.82 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.3240 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 148 M Total Cash Per Share 2.82 Total Debt 17 M
Total Debt To Equity 12.69 Current Ratio 4.82 Book Value Per Share 2.59
All Measures
Short Ratio 864.00 % Message Board Id finmb_301925264 Shares Short Prior Month 9 M
Return On Equity -0.9894 City South San Francisco Uuid 52e646b9-c1df-34ee-b25a-cfac131940e6
Previous Close 1.49 First Trade Date Epoch Utc 1 B Book Value 2.59
Beta 1.04 Total Debt 17 M Volume 330462
Price To Book 0.5821 Fifty Two Week Low 1.19 Total Cash Per Share 2.82
Shares Short Previous Month Date 1 B Target Median Price 6.00 Audit Risk 7
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 9.33
Net Income To Common -151159008 Short Percent Of Float 0.2374 Implied Shares Outstanding 52 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 856090
Average Volume10days 856090 Total Cash 148 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0191 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 1.49
Target Low Price 3.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.56
Open 1.52 Free Cashflow -74554248 State CA
Dividend Yield 0.00 % Return On Assets -0.4924 Time Zone Short Name EST
Board Risk 6 Trailing Eps -2.97 Day Low 1.47
Address1 323 Allerton Avenue Shares Outstanding 52 M Compensation Risk 9
Price Hint 4 Target High Price 25.00 Website https://www.alxoncology.com
52 Week Change -0.8074 Average Volume 675123 Forward Eps -2.71
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 463.10 %
Is_sp_500 False Regular Market Day High 1.52 Profit Margins 0.00 %
Debt To Equity 12.69 Fifty Two Week High 17.82 Day High 1.52
Shares Short 7 M Regular Market Open 1.52 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.1370
Operating Cashflow -129544000 Currency USD Time Zone Full Name America/New_York
Market Cap 79 M Is_nasdaq_100 False Zip 94080
Quote Type EQUITY Industry Biotechnology Long Name ALX Oncology Holdings Inc.
Overall Risk 8 Regular Market Day Low 1.47 Held Percent Institutions 0.8823
Current Price 1.51 Enterprise To Ebitda 0.3240 Financial Currency USD
Current Ratio 4.82 Industry Disp Biotechnology Number Of Analyst Opinions 6
Country United States Float Shares 27 M Two Hundred Day Average 7.52
Governance Epoch Date 1 B Enterprise Value -51573912 Forward PE -0.6622
Regular Market Volume 330462 Ebitda -159012000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.

The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.

It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer.

In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses.

It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.